Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Vito Palombella was terminated as Chief Scientific Officer at Surface Oncology, Inc..
- Action
- terminated
- Role
- Chief Scientific Officer
Exact text from the filing
In connection with the June Reduction in Force, the following members of the Company’s executive team will be leaving the Company to pursue new opportunities, effective June 23, 2023: Vito Palombella, Ph.D, the Company’s current Chief Scientific Officer, and Henry Rath, the Company’s current Chief Business Officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Henry Rath was terminated as Chief Business Officer at Surface Oncology, Inc..
- Action
- terminated
- Role
- Chief Business Officer
Exact text from the filing
In connection with the June Reduction in Force, the following members of the Company’s executive team will be leaving the Company to pursue new opportunities, effective June 23, 2023: Vito Palombella, Ph.D, the Company’s current Chief Scientific Officer, and Henry Rath, the Company’s current Chief Business Officer.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.98
Surface Oncology, Inc. entered into Agreement and Plan of Merger with Coherus BioSciences, Inc., Crimson Merger Sub I, Inc. and Crimson Merger Sub II, LLC (effective 2023-06-15).
- Action
- entry
- Agreement
- merger
- Counterparty
- Coherus BioSciences, Inc., Crimson Merger Sub I, Inc. and Crimson Merger Sub II, LLC
- Effective
- 2023-06-15
Exact text from the filing
On June 15, 2023, Surface Oncology, Inc., a Delaware corporation (the " Company "), entered into an Agreement and Plan of Merger (the " Merger Agreement ") by and among Coherus BioSciences, Inc., a Delaware corporation (" Parent "), Crimson Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Parent (" Merger Sub I ") and Crimson Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (" Merger Sub II " and together with Merger Sub I, the " Merger Subs ").
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.85
Surface Oncology, Inc. announced a restructuring with charges of reduction in force as part of its cost savings efforts that is expected to result in the termination of approximately 50% of the Company’s remaining workforce affecting approximately 50% of the Company’s remaining workforce (approximately 50% of the Company’s remaining workforce).
- Type
- restructuring
- Charge
- reduction in force as part of its cost savings efforts that is expected to result in the termination of approximately 50% of the Company’s remaining workforce
- Affected area
- approximately 50% of the Company’s remaining workforce
- Headcount
- approximately 50% of the Company’s remaining workforce
Exact text from the filing
Concurrent with the signing of the Merger Agreement, the Company announced a reduction in force as part of its cost savings efforts that is expected to result in the termination of approximately 50% of the Company’s remaining workforce (the “ June Reduction in Force ”).
View on SEC.gov